Our prediction suggests a more specific role for ACBD6 in prostate cancer as a potential suppressor of NFκB activity and downstream inflammation, as it was highly co-expressed with the two NFκB inhibitors, NFκB IA and NFκBIE (Pringle et al., 2012; Wu et al., 2006) (Fig. 2). This evidence concerns the gene NFKB1 and prostate carcinoma.